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Abstract: The high levels of dengue-virus (DENV) seroprevalence in areas where the Zika virus
(ZIKV) is circulating and the cross-reactivity between these two viruses have raised concerns on
the risk of increased ZIKV disease severity for patients with a history of previous DENV infections.
To determine the role of DENV preimmunity in ZIKV infection, we analyzed the T- and B-cell
responses against ZIKV in donors with or without previous DENV infection. Using peripheral blood
mononuclear cells (PBMCs) from donors living in an endemic area in Colombia, we have identified,
by interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assay, most of the immunodominant
ZIKV T-cell epitopes in the nonstructural (NS) proteins NS1, NS3, and NS5. Analyses of the T- and
B-cell responses in the same donors revealed a stronger T-cell response against peptides conserved
between DENV and ZIKV, with a higher level of ZIKV-neutralizing antibodies in DENV-immune
donors in comparison with DENV-naïve donors. Strikingly, the potential for antibody-mediated
enhancement of ZIKV infection was reduced in donors with sequential DENV and ZIKV infection in
comparison with donors with DENV infection only. Altogether, these data suggest that individuals
with DENV immunity present improved immune responses against ZIKV.
Keywords: dengue virus; zika virus; T-cell epitopes; cross-reactive T cells; immunodominance;
neutralizing antibodies; antibody-dependent-enhancement (ADE)
1. Introduction
The Zika virus (ZIKV) is a flavivirus transmitted by Aedes species mosquitoes. It is a single
positive-stranded RNA virus closely related to the yellow-fever virus, dengue virus (DENV), and West
Nile virus [1]. Initially isolated in the Zika forest in Uganda in 1947 [2], it caused an explosive outbreak
for the first time in Yap Island, Federated States of Micronesia in 2007 [3]. Subsequent outbreaks with
higher number of cases occurred in 2013–2014 in French Polynesia and other South Pacific Islands,
and, more recently, in the Americas [4–9]. Although initially believed to only cause mild, self-limiting
disease, a causal relationship between ZIKV and neurological complications, such as Guillain-Barré
syndrome or congenital malformations, was established during the 2013 and 2015 outbreaks in French
Polynesia and Brazil [10–13].
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While mutations in ZIKV genome might have contributed to its increased pathogenicity or
explosive spread [9,14,15], one of the most important concerns today is related to the high level of
DENV seroprevalence in areas where ZIKV is circulating [16]. Indeed, recent studies have shown that
anti-DENV antibodies may enhance ZIKV infection and increase disease severity [17–21]. Given these
constraints, and the lack of appropriate treatment for ZIKV infection, there is an urgent need to develop
a vaccine against this infectious disease.
While antibodies against the E protein of DENV or ZIKV were shown to be highly cross-reactive,
T cells can be cross-reactive or not, depending on the targeted peptides. A low degree of CD4 T-cell
cross-reactivity between DENV and ZIKV was indeed observed in human donors immune to one
of these viruses [18], whereas DENV/ZIKV cross-reactive T cells were identified in humans and in
DENV-immune mice after challenge with ZIKV [22–24]. Considering the sequence identity between
DENV and ZIKV for the structural proteins capsid and envelope, and the nonstructural proteins NS3
and NS5, which represent the main targets of DENV-specific CD4 and CD8 T cells, respectively, and the
protective role of DENV-specific T cells [25,26], efforts are currently directed towards the mapping
of T-cell epitopes to design new and more effective vaccines against ZIKV [27]. Predictions of T-cell
antigens have been conducted by modeling potential epitopes from the ZIKV proteome that could
bind to different HLA class I or class II alleles [23,28–30], or by analyzing ex vivo T-cell responses in
transgenic mice expressing human HLA-B*07:02 and HLA-A*01:01 molecules [23]. More recently, ZIKV
epitopes targeted by CD4 and CD8 T cells have also been identified from human donors living in ZIKV-
and DENV-endemic regions [22]. Quite unexpectedly, while the majority of T-cell responses observed
upon infection with DENV were directed against the nonstructural proteins NS3, NS4B, and NS5,
ZIKV-specific T cells preferentially recognize structural proteins E, prM, and C, with conserved
epitopes between DENV and ZIKV representing the main targets for cross-reactive T cells [22,23].
Furthermore, in the light of the recent identification of DENV/ZIKV cross-reactive T cells in human
and in different animal models [22,24,31–34], the precise identification of ZIKV T-cell epitopes in the
human that activate these cross-reactive T cells is essential to assess the role of these T cells in ZIKV
infection and disease. In the present study, we have identified these epitopes from blood donors with
a history of ZIKV-only infection or both DENV and ZIKV infection.
Using PBMCs from Colombian blood donors with previous ZIKV infection, we have first
established a detailed map of the distribution of ZIKV T-cell epitopes, by quantifying ex vivo
IFN-γ responses against peptides covering the whole ZIKV proteomic sequence by enzyme-linked
immunosorbent spot (ELISPOT) assay. Measurement of the magnitude of T-cell responses (mediated
by CD4 and/or CD8 T cells) against these peptides allowed us to identify immunodominant epitopes
that induce strong responses in donors carrying specific HLA alleles. More specifically, we show
that the nonstructural proteins NS1, NS3, and NS5 contain most of the immunodominant epitopes
that induce a strong T-cell response. In donors with a history of DENV infection, the strongest T-cell
responses were directed against peptides of the NS5 protein with a high level of amino acid identity
with the four serotypes of DENV, and some matched previously described DENV CD8+ T-cell epitopes,
suggesting the activation of cross-reactive T cells.
The neutralizing or enhancing activity of ZIKV-induced antibodies from the same donors were
also analyzed using a flow cytometry-based assay. Results show that ZIKV infection in DENV-immune
individuals resulted in increased levels of neutralizing antibodies against ZIKV, in comparison with
DENV-naïve individuals, and in reduced potential for antibody enhancement of ZIKV infection,
in comparison with DENV-immune ZIKV-naïve individuals. Altogether, these data strongly suggest
that a sequential DENV and ZIKV infection may improve the immune protection against ZIKV
infection but not against DENV infection.
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2. Materials and Methods
2.1. Ethics Statement
Human blood samples were taken after obtaining the informed consent from healthy adult donors
from the Fundación Hematológica Colombia (Bogotá D.C., Colombia) in accordance with the tenets of
the Declaration of Helsinki. All protocols described in this study were approved by the institutional
review board (IRB) of the EL Bosque University (Colombia). Donors were of both sexes and between
20 and 60 years of age. A total of 82 samples were obtained from different ZIKV-endemic areas near
Bogotá D.C. (mainly from Villavicencio, Meta) between September and November 2016.
2.2. Human Blood Samples
PBMCs were purified by density gradient centrifugation (Lymphoprep™, Stemcell Technologies,
Vancouver, BC, Canada), resuspended in fetal bovine serum (FBS) (Gibco Invitrogen, Carlsbad, CA,
USA) containing 10% dimethyl sulfoxide and cryopreserved in liquid nitrogen. Eleven of the 82 blood
samples obtained had to be excluded from the study due to poor viability of cells.
2.3. Viruses and Cell Lines
The in vitro assays were conducted using the DENV1 KDH0026A strain (provided by Dr L.
Lambrechts, Institut Pasteur, Paris), DENV2 R0712259 strain (provided by Dr. A.-B. Failloux, Institut
Pasteur, Paris), DENV3 KDH0010A strain (provided by Dr. L. Lambrechts, Institut Pasteur, Paris),
DENV4 VIMFH4 (from the Institut Pasteur Collection), and ZIKV FG15 strain (provided by Dr. D.
Rousset, Institut Pasteur, Cayenne). All viruses were grown using the Aedes Albopictus mosquito
cell line C6/36 cultured in Leibovitz’s L-15 medium supplemented with 10% fetal bovine serum
containing 0.1 mM nonessential amino acids and 1 × tryptose phosphate broth. Vero-E6 and
DC-SIGN-expressing U937 cells were kindly provided by Dr M. Flamand and Dr B. Jacquelin (Institut
Pasteur, Paris), respectively.
2.4. HLA Typing
Genomic DNA isolated from PBMCs of the study subjects by standard techniques (QIAmp,
Qiagen, Hilden, Germany) was used for HLA typing. High-resolution Luminex-based typing for
HLA class I and class II molecules (alleles A, B, C, and DRB1, respectively) was used according to the
manufacturer’s protocol (Sequence-Specific Oligonucleotides (SSO) typing; Immucor, Inc., Peachtree
City, GA, USA).
2.5. Serology
ZIKV seropositivity was determined using a recombinant antigen-based (ZEDIII antigen) indirect
ELISA, as previously described [35]. Briefly, 96-well plates (Nunc, Life Technologies, Rochester, NY) were
coated overnight at 4 ◦C with 50 ng of antigen in PBS. After washing, 200 µL PBS containing 3% skimmed
milk and 0.1% Tween-20 were added for 1 h at 37◦. The blocking solution was replaced by 100 µL of
plasma diluted 1:500 in PBS containing 1.5% BSA and 0.1% Tween-20, and plates were incubated at 37 ◦C
for 60 min. After 3 washes, bound antibodies were detected with a horseradish peroxidase-conjugated
goat antihuman IgG immunoglobulin (Rockland Immunochemicals Inc. Limerick, PA, USA). Following
incubation at 37 ◦C for 1 h and 3 washes, 100 µL of a substrate solution containing TMB (KPL SeraCare,
Milford, MA, USA) was added. After 15 min incubation, the optical density (OD) was determined at
650 nm with an automated plate reader (Tecan infinite 200 pro). Each plasma sample was tested in duplicate.
Plasma samples, obtained from individuals with positive DENV IgG serology collected before the ZIKV
outbreak, were used as negative controls. The cut-off was calculated from the negative controls and was
0.196. DENV seropositivity was determined by indirect ELISA for IgGs (Panbio; Alere Inc., IL, USA),
and by capture ELISA for IgM (Tecnosuma, Havana, Cuba) following the manufacturer’s instructions.
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The quantification of neutralizing and enhancing activities of antibodies against DENV and ZIKV infections
was determined using a flow cytometry-based assay, as described previously [36,37]. Briefly, 10-fold serial
dilutions of plasma samples were incubated at 37 ◦C for 1 h with either a dilution of virus inducing 7–15%
of infection (for neutralization assay) or a dilution of virus inducing between 0.5% and 2% infection (for
Antibody-Dependent Enhancement (ADE) Assay). Virus–antibody mixture was then added to 5 × 104 cells
(U937-DC-SIGN cells for neutralization of DENV1-4 infection, Vero cells for neutralization of ZIKV infection,
or K562 cells for the ADE assay), for 2 h at 37 ◦C, after which cells were washed 2 times with fresh medium
and then incubated for 24 h. The cells were then fixed with 4% paraformaldehyde, stained with 4G2
antibody conjugated to Alexa Fluor™ 488, and the percentage of infected cells was measured by flow
cytometry. The neutralization titer of antibodies was expressed as the reciprocal dilution of plasma at
which 50% of the virus was inhibited. Plasma samples from donors collected before ZIKV outbreak or from
negative samples provided from the Kits to detect anti-DENV antibodies did not reveal any neutralization
activity against ZIKV or DENV infection, respectively. For the ADE assay, the peak titer was expressed as
the logarithm of reciprocal dilution of plasma at which the percentage of infection was maximal. Following
the ELISA and neutralization assays, from the 71 plasma samples selected for this study, a total of 9
samples from ZIKV-immune and DENV-naïve individuals and 11 samples from DENV- and ZIKV-immune
(DENV/ZIKV-immune) individuals were further selected for ELISPOT analysis.
2.6. RT-PCR Assays for Detection of DENV and ZIKV
RNA was extracted from plasma using the QIAamp Viral RNA Mini kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. Samples were tested for DENV and ZIKV using a specific
nested-PCR assay, as previously described [38]. Detection of ZIKV was confirmed in 3 out of the 9
plasma samples from ZIKV-immune DENV-naïve donors and in 6 out of the 11 plasma samples from
DENV/ZIKV-immune donors, whereas DENV was detected in 2 out of the 11 plasma samples from
DENV/ZIKV-immune donors (Table 1).
Table 1. Categories of donors in the study cohort.
Group Nb of Samples ZIKV Status 1,2 DENV Status 1,2 Age 3 (Year) Sex (% Male)
A 14 Negative Positive 17 (84–1) 36
B 9 Positive Negative 30 (184–1) 56
C 5 Positive Positive 27 (213–5) 20
D 4 Acute Positive 33 (205–4) 25
E 2 Acute Acute 27 (252–8) 50
1 Previous exposure to ZIKV or DENV was determined by the presence of ZIKV- or DENV-specific IgG antibodies;
negative, absence of virus-specific IgG antibodies; positive, presence of virus-specific IgG antibodies; 2 acute
infection with ZIKV or DENV was confirmed by RT-PCR; 3 expressed as the mean age of the group (range). ZIKV:
Zika virus; DENV: dengue virus.
2.7. Viral Sequences
The identical amino acid sequence of 2 Zika viruses from Colombia (KX087102 and KU820897) was
used as a reference for the set of overlapping 15-mer peptides. A total of 50 full-length protein-coding DENV
sequences from Colombia (serotype 1: 14 sequences; serotype 2: 16 sequences; serotype 3: 13 sequences;
serotype 4: 7 sequences) were retrieved from GenBank and used for pairwise sequence identity comparisons.
2.8. Peptides
All peptides were synthesized by Mimotopes (Victoria, Australia). A total of 853 15-mer peptides
overlapping by 11 amino acids and 197 9-mer peptides overlapping by 8 amino acids were tested by
ELISPOT assay. For the identification of T-cell epitopes, 15-mer peptides were combined into pools of
12 peptides, and individual peptides from the positive pools were tested in a second ELISPOT assay.
Following the identification of the positive 15-mer peptides, and according to their HLA class I or class II
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restriction potential (predicted or shared between at least two donors), 9-mer peptides were synthesized
and tested individually.
2.9. Ex Vivo IFN-γ ELISPOT Assay
PBMCs (2 × 105) were incubated in 96-well flat-bottom plates (MSIPS 4510, Millipore, Millipore,
Burlington, MA, USA) coated with anti-IFN-γ mAb (clone 1-D1K, Mabtech, Stockholm, Sweden) with
0.2 mL of complete RPMI containing 10% human AB serum with pools of 12 peptides (2 g/mL, final
concentration) or individual peptides (1 g/mL final concentration) for 20 h. Following a 20 h incubation at
37 ◦C, the wells were washed with PBS/0.05% Tween 20 and then incubated with biotinylated anti-IFN-γ
mAb (clone 7-B61-, Mabtech, Stockholm, Sweden) for 1 h 30 min. The spots were developed using
streptavidin-alkaline phosphatase (Mabtech, Stockholm, Sweden) and BCIP/NBT substrate (Promega,
Madison, WI, USA) and counted using an automated ELISPOT reader (Immunospot, Cellular Technology
Limited, Cleveland, OH, USA). The number of IFN-γ-producing cells was expressed as spot-forming cells
(SFC) relative to 1 × 106 PBMCs. Values were calculated by subtracting the number of spots detected in the
nonstimulated control wells. Values were considered positive if they were equal to or greater than 20 spots
and at least three times above the means of the unstimulated control wells. As a positive control, cells were
stimulated with CEF peptide pool (Mabtech, Stockholm, Sweden).
2.10. Immunogenicity and HLA Restrictions Prediction
The evaluation of binding possibilities of peptides to MHC class I and class II alleles was analyzed
using the NetMHCpan3.0 and NetMHCIIpan3.1 servers, respectively [39,40].
2.11. Statistics
All data were analyzed with Prism software version 7.0 (GraphPad Software Inc., La Jolla, CA, USA).
Statistical significance was determined using the nonparametric two-tailed Mann–Whitney test to compare
two independent groups. Differences were considered significant at p < 0.05.
3. Results
3.1. Identification of Immunodominant Regions of the ZIKV Proteome
To investigate T-cell immunity induced after ZIKV infection, we examined responses from blood
donors living in a ZIKV-endemic area in gamma interferon (IFN-γ)-specific ELISPOT assays. Blood samples
from all study participants were first tested for the presence of Zika virus IgG, and dengue virus IgM and
IgG by ELISA, and for the presence of virus-specific antibodies by flow cytometry-based neutralization
assay against ZIKV and the four DENV serotypes. Recent infection with ZIKV was confirmed by RT-PCR
in three out of nine plasma samples from ZIKV-immune DENV-naïve donors, and in six out of 11 plasma
samples from DENV/ZIKV-immune donors, whereas recent infection with DENV was detected in two out
of 11 plasma samples from DENV/ZIKV-immune donors (Table 1).
To confirm previous DENV or ZIKV infection in the PCR-negative samples, all samples were
screened for specific neutralizing antibodies against the four DENV serotypes and against ZIKV. While all
samples from ZIKV-immune DENV-naïve donors (donors from group B) revealed significant levels
of neutralizing antibodies against ZIKV, they did not neutralize DENV1-4 infection, confirming the
absence of DENV-specific antibodies in these donors (Figure S1). On the contrary, all samples from
DENV/ZIKV-immune donors (donors from groups C, D, and E) revealed high neutralization titers against
both ZIKV and DENV (Figure S1). Because anti-DENV antibodies have been shown to cross-react with
ZIKV [18,20], blood samples collected before the ZIKV outbreak were used as negative controls for
ZIKV neutralization. In these samples (group A donors), strong neutralization activity was measured
against at least one DENV serotype, whereas low neutralization activity was detected against ZIKV,
in contrast to samples from DENV/ZIKV-immune (groups C, D, and E) donors showing high neutralization
activity against both DENV and ZIKV (Figure S1). Based on these data, two groups of donors were
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selected for further studies, donors from group B having only high levels of ZIKV-neutralizing antibodies,
and donors from groups C, D, and E having both DENV- and ZIKV-neutralizing antibodies. PBMCs
from all 20 ZIKV-seropositive donors (groups B to E) were screened for T-cell reactivity against pools
of 15-mer peptides (overlapping by 11 amino acids) spanning the entire ZIKV proteome. Analysis of
the response magnitude (as SFC per 106 cells) and frequency of responding donors revealed that the
nonstructural proteins NS1, NS3, and NS5 were the most vigorously and frequently recognized proteins,
and accounted for more than 65% of the total response (Figure 1). As these donors were selected in DENV-
and ZIKV-endemic areas, and as these viruses share an overall 43% protein-sequence identity (with up
to 68% for the nonstructural proteins), we sought to distinguish between the ZIKV-specific epitopes and
those shared by both viruses. Among the 20 ZIKV-seropositive blood donors, 11 individuals had both
anti-DENV and anti-ZIKV IgG antibodies (C, D, and E donors) and nine individuals did not reveal any
detectable anti-DENV antibodies (B donors) (Table 1 and Figure S1). Strikingly, NS1, NS3, and NS5 proteins
represented 13%, 31%, and 32% of the total response, respectively, in donors from group B (Figure 1A)
and 15%, 16%, and 36% of the responses in donors from groups C, D, and E (Figure 1B), whereas the NS3,
NS4B, and NS5 proteins have been reported to account for 31%, 15%, and 22% of the DENV-specific T-cell
response, respectively [25,41–43].
Figure 1. Cumulative IFN-γ responses (as spot-forming cells (SFCs) per million cells) for each
overlapping peptide spanning the ZIKV proteome. (A) SFCs per million cells are shown for donors
from group B; (B) SFCs per million cells are shown for donors from groups C, D, and E. The heat map
indicates the number of donors with a positive IFN-γ response to each peptide within each protein
(C, capsid; M, membrane; E, envelope, NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The numbers
below each graph represent percentages of the total response for each protein.
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The analysis of the T-cell responses in these two groups of donors confirmed that NS1, NS3,
and NS5 are the main targets for T cells in ZIKV-infected donors, regardless of a previous infection with
DENV. From the 853 peptides spanning the entire ZIKV proteome, 410 peptides elicited a significant
T-cell response, some of which being recognized by multiple donors. For most antigenic peptides,
the HLA class I and class II alleles of the responding donors coincide with the alleles predicted to
bind to this epitope [39,40]. Among the epitopes inducing a strong response in ZIKV-immune only
and DENV/ZIKV-immune donors, several 15-mer peptides contained sequences predicted to bind
strongly to at least one allele expressed by the responding donors (Table 2 and Table S1).
Table 2. HLA class I- or class II-restricted T-cell epitopes identified in ZIKV proteins.
Peptide 1 Sequence SFC/Million PBMC 2 HLA Score 3
C869–4 KDLAAMLRI 65 B*55:01 1.4
B*40:02 2.0
C899–7 AAMLRIINA 75 A*02:01 4.5
NS1637–7 MENIMWRSVEGELNA 310 DRB1*04:05 50
NS1687–6 WRSVEGELN 206 B*40:02 48
B*18:01 48
NS11671–75 VWLKVREDY 75 A*29:02 1.3
NS12802–88 CPGTKVHVE 170 B*35:01 8.5
B*35:31 6.5
NS32192–33 TVILAPTRVVAAEME 165 DRB1*08:02 1.5
NS33113–25 AAIFMTATPPGTRDA 470 DRB1*04:01 4.0
NS33133–21 IFMTATPPG 30 A*24:02 5.0
NS33143–22 FMTATPPGT 85 A*02:17 5.5
NS4B1121–20 AIILLVAHY 88 A*29:02 0.6
A*11:01 3.5
NS4B1151–23 LLVAHYMYL 68 A*02:05 0.3
NS4B1161–24 LVAHYMYLI 35 A*69:01 0.15
A*02:05 0.2
NS52983–06 NHPYRTWAY 4 358 B*35:01 3.0
NS52993–07 HPYRTWAYH 4 308 B*35:01 0.4
NS53023–10 RTWAYHGSY 205 A*01:01 0.5
NS53483–56 TPYGQQRVF 4 1681 B*35:31 0.7
B*35:01 0.3
NS54254–33 EAVNDPRFW 465 B*44:03 5.0
B*15:17 7.0
B*35:01 5.0
NS54614–75 KKQGEFGKAKGSRAI 405 DRB1*07:01 32
NS54734–87 RAIWYMWLGARFLEF 505 DRB1*07:01 16
NS56096–17 YALNTFTNL 42 B*35:43 0.4
B*35:31 0.25
1 The position of peptides were determined according to NCBI reference sequence YP_002790881.1; 2 Cumulative
SFC/million PBMC; 3 Calculated using NetMHCpan 3.0 or NetMHCIIpan3.1 server; 4 Peptides identified previously
in human individuals infected with DENV and ZIKV [22].
For instance, the NS2B1171–31 peptide contains a 10-mer sequence predicted to bind strongly to the
HLA-A*03:01 and -A*11:01 molecules expressed by the responding donor 55 (Table S1). In other cases,
multiple responding donors express at least one common allele with strong potential for binding to the
stimulating peptide. This holds for the E4554–69 peptide in the envelope that contains the 9-mer and the
10-mer sequences predicted to bind to the HLA-B*51:01 and HLA-A*02:01 alleles, both alleles being
expressed by the responding donors 1 and 77 (Table S1). This also applies to the NS5132–7 peptide,
which induced a strong response in donors 55 and 69 that share the HLA-B*35:01 allele, this allele being
predicted to bind to the 9-mer peptide MSALEFYSY with a high affinity (Table S1). Interestingly, this
epitope was also shown to induce a significant response in transgenic mice carrying the HLA-A*01:01
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molecule, which is expressed by donor 69 [23]. Similarly, a strong T-cell response was observed against
the NS55465–60 peptide in donors 28, 53, and 66 that express the HLA-B*40:02 and -B*44:03 alleles,
and against the NS56056–19 peptide in donors 33 and 59 that share the predicted HLA-A*24:02 allele
(Table S1). Finally, we have also identified several 9-mer and 15-mer immunodominant epitopes in the
Capsid, NS1, NS3, NS4B, and NS5 proteins, which induced substantial T-cell responses in donors that
share one or several alleles with a strong potential for binding to these peptides (Table 2).
Within the NS3 and NS5 proteins, several epitopes were previously described as
immunodominant epitopes, either predicted or validated experimentally after DENV infection or
vaccination in humans or after ZIKV infection in mice and in humans [22,23,29,44,45]. Indeed, among
the 9-mer peptides identified in DENV/ZIKV-immune (groups C, D, and E) donors, the NS52933–07,
NS52973–11, and NS53453–59 have been already detected in PBMCs from HLA-B*35:01 individuals after
infection with DENV1, DENV2, or vaccination with DENV live attenuated vaccine (DLAV), with a
lysine-to-arginine and a phenylalanine-to-tyrosine amino acid substitution at residues 302 and 350 in
the NS52973–11 and NS53453–59 peptides from ZIKV, respectively [22,43,44,46] (Table 2). These results
thus confirm that these NS5 peptides contain nested epitopes restricted by the HLA-B*35:01 molecule.
Yet the 15-mer NS32192–33 peptide, which contains the APTRVVAAEM epitope, induced a substantial
response in two donors with a history of ZIKV and DENV infection that express neither HLA-B*07:02
nor B*35:01 (Table S1), although these alleles were expressed in responding donors vaccinated with
the live attenuated DENV vaccine DLAV or in ifnar-/- HLA-B*07:02 transgenic mice or in humans
after ZIKV infection [22,23,44]. This suggests that the NS32192–33 peptide contains another epitope or a
promiscuous epitope that binds to other HLA alleles besides HLA-B*07:02 or B*35:01 (Table 2).
3.2. Broader Responses with a Higher Magnitude in DENV/ZIKV-Immune Donors
Given the ZIKV-specific antibody response against NS1 and the low level of CD4 T-cell
cross-reactivity between DENV and ZIKV against the E and NS1 proteins [18], we wished to compare,
among the immunodominant epitopes, the T-cell responses in PBMCs from ZIKV-immune only (group
B) donors with those from DENV/ZIKV-immune (groups C, D, and E) donors. First, comparison of
the frequency of responding T cells between these two different types of donors underlined the higher
magnitude of response in donors with evidence of past or current ZIKV and DENV infection relative
to donors with a history of ZIKV infection only (Figure 1A,B). The number of stimulating peptides per
donor for each viral protein, as well as the average response per donor differed in these two groups,
with a significantly broader response against the E, NS3, and NS5 proteins and a higher magnitude
of response in DENV/ZIKV-immune (Figure 2A,B). To determine whether this difference concerned
only a small number of peptides that elicit a stronger response in each donor, or if it concerned the
majority of the peptides, we plotted the frequency of responses against the different peptides, per
donor, in the two different groups. Two out of nine individuals among the ZIKV-immune DENV-naïve
(group B) donors revealed a median response higher than 100 SFC/million cells, whereas six out of
11 DENV/ZIKV-immune (groups C, D, and E) donors developed this strong response, which was
also directed against a higher number of peptides (Figure 2C,D). This result reveals the activation of a
higher frequency of T cells against ZIKV peptides, with a higher magnitude of response, in donors
previously or currently infected with DENV, in comparison with naïve donors. This strongly argues
for the existence of cross-reactive T cells, these T cells being primed during the initial infection with
DENV and expanded thereafter during the following infection with ZIKV, as shown recently in mice
and in humans, after sequential infection with DENV and ZIKV [22,23].
Viruses 2018, 10, 480 9 of 20
Figure 2. DENV/ZIKV-immune donors reveal a broader T-cell response with a higher magnitude.
(A) Breadth and (B) magnitude of responses in donors with a history of ZIKV infection only or DENV
and ZIKV infection. Each dot represents one donor (open circles, ZIKV-immune DENV-naïve donors;
filled circles, DENV/ZIKV-immune donors) and the bars represent the median value for each group
of donors. The p values were calculated using the nonparametric two-tailed Mann–Whitney test.
Frequency of responses against individual peptides, per donor, in ZIKV-immune DENV-naïve (C) and
DENV/ZIKV-immune (D) donors. Each dot represents one peptide. The bars represent the median
response for each donor.
3.3. DENV/ZIKV-Cross-Reactive T Cells Mainly Target the NS5 Protein
To identify, more specifically, ZIKV-specific peptides and DENV/ZIKV cross-reactive peptides,
we compared the sequences of the most immunodominant epitopes recognized by both types of
donors. The NS1 and NS3 proteins contain a high proportion of peptides that elicit strong responses
in both ZIKV-immune DENV-naïve and DENV/ZIKV-immune donors, whereas the E protein and
to a higher extent the NS5 protein contain a majority of peptides inducing a strong response only
in DENV/ZIKV-immune donors (Figure 2A and Table 3). This suggests that the NS1 and NS3
proteins contain more ZIKV-specific epitopes, whereas the NS5 protein contains more epitopes
shared by DENV and ZIKV and recognized by cross-reactive T cells. Strikingly, most of the peptides
recognized only by DENV/ZIKV-immune donors exhibit high degree of identity with the four DENV
serotypes. For instance, in the NS1 protein, two out of the five epitopes that induced a response in
ZIKV-immune DENV-naïve donors revealed a sequence identity higher than 60% with the four DENV
serotypes, whereas eight out of the 11 epitopes in the NS5 protein that induced a strong response
in DENV/ZIKV-immune donors showed a sequence identity higher than 67% with the four DENV
serotypes (Table 3). Altogether, these data strongly support the activation of cross-reactive T cells
induced after DENV and ZIKV infection, which recognize common epitopes between DENV and ZIKV
mainly located in the NS5 protein, and which dominate the T-cell response against ZIKV.
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Table 3. Immunodominant epitopes in ZIKV- and DENV/ZIKV-immune donors.
Peptide 1 Sequence
ZIKV DENV/ZIKV Identity (%)
Donors SFC/million
PBMC 2
Donors SFC/million
PBMC 2
DENV Serotypes
1 2 3 4
C49-63 AILAFLRFTAIKPSL 60 60 28,63 365 60 53 60 40
E67-81 DMASDSRCPTQGEAY 33 465 67 53 67 53
E87-101 DTQYVCKRTLVDRGW 56 505 67 54 73 67
NS119-33 VFVYNDVEAWRDRYK 21,46,60 195 28,56 380 47 33 47 40
NS155-69 CGISSVSRMENIMWR 35,46 125 56 275 67 66 60 60
NS191-105 GSVKNPMWRGPQRLP 21,35,46,60 275 28 165 13 33 20 33
NS1107-121 PVNELPHGWKAWGKS 28,53 430 40 47 47 50
NS1147-161 HRAWNSFLVEDHGFG 46 40 33,53 445 67 73 67 76
NS1163-177 FHTSVWLKVREDYSL 46 35 20,28,55 450 47 46 53 47
NS1195-209 HSDLGYWIESEKNDT 28,33 615 80 73 66 73
NS2B117-131 AAGAWYVYVKTGKRS 55 445 33 33 27 27
NS3131-145 PAGTSGSPILDKCGR 21,42 405 26,55,63 495 53 61 53 54
NS3143-157 CGRVIGLYGNGVVIK 21 350 20,55,63,66 550 60 67 72 80
NS3311-325 AAIFMTATPPGTRDA 28,33 470 80 80 93 80
NS513-27 KARLNQMSALEFYSY 55,69 405 53 47 53 40
NS5293-307 WFFDENHPYRTWAYH 55,69 1620 67 67 60 67
NS5297-311 ENHPYRTWAYHGSYE 55,69 1330 80 80 73 80
NS5325-339 VVRLLSKPWDVVTGV 28,55,66 495 73 80 73 67
NS5345-359 TDTTPYGQQRVFKEK 33,55,69 4195 93 93 93 93
NS5373-387 QVMSMVSSWLWKELG 60 130 55,66,69 340 40 53 47 47
NS5461-475 KKQGEFGKAKGSRAI 28,53 405 93 93 93 87
NS5465-479 EFGKAKGSRAIWYMW 28,53,55,56 1085 100 100 100 93
NS5473-487 RAIWYMWLGARFLEF 28,55 505 100 100 93 100
NS5481-495 GARFLEFEALGFLNE 28,53,56,63 1870 93 100 93 100
NS5546-560 RFDLENEALITNQME 28,53,66 515 60 47 53 60
NS5573-586 TYQNKVVKVLRPAEK 28,53,56 615 73 67 73 80
NS5849-863 CGSLIGHRPRTTWAE 60 90 33,55 340 67 67 67 67
1 The position of peptides was determined according to NCBI Reference Sequence YP_002790881.1; 2 Cumulative
SFC/million PBMC.
3.4. Increased Neutralizing Antibody Titer against ZIKV in DENV/ZIKV-Immune Donors
To determine whether the high T-cell response in DENV/ZIKV-immune donors is also
accompanied by a strong antibody response against ZIKV in these donors, we analyzed the ability
of ZIKV-specific antibodies to bind and to neutralize ZIKV and DENV1-4. Plasma samples from
ZIKV-immune DENV-naïve (group B) donors, DENV/ZIKV-immune (groups C, D, and E) donors,
as well as DENV-immune ZIKV-naïve (group A) donors were used to analyze the ability of antibodies
to bind to ZIKV EDIII (ZEDIII) and to neutralize ZIKV infection. Results revealed an increased level
of antibodies that bind to ZEDIII in plasma samples from ZIKV-immune DENV-immune donors,
in comparison with plasma samples from ZIKV-immune DENV-naïve donors (Figure 3A). On the
contrary, plasma samples from DENV-immune ZIKV-naïve donors did not reveal any binding activity
on ZEDIII.
Knowing that EDIII-specific antibodies are more efficient in neutralizing ZIKV infection [47],
we then asked whether the higher binding capacity to ZEDIII is also accompanied by a stronger
neutralization against ZIKV infection. Comparison between the neutralization activity of antibodies
between ZIKV-immune DENV-naïve (group B) donors and DENV/ZIKV-immune (groups C, D,
and E) donors revealed a significantly higher neutralization potential against ZIKV in donors
with evidence of past or current ZIKV and DENV infection (Figure 3B). Interestingly, while most
DENV-immune ZIKV-naïve donors did not show any neutralization against ZIKV infection, two out
of 14 DENV-immune donors in this group could also neutralize ZIKV (Figure 3B and Figure S1), even
though these two plasma samples were collected before the ZIKV outbreak, confirming the induction
of ZIKV-cross-neutralizing and non-EDIII-binding antibodies in DENV-immune donors [18,20,48].
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Figure 3. Analysis of ZIKV EDIII (ZEDIII)-binding and ZIKV- and DENV-neutralizing activity of
plasma samples from DENV- and/or ZIKV-immune donors. (A) Detection of ZEDIII-binding antibodies
by ELISA; (B) quantification of neutralizing activity against ZIKV; (C) quantification of neutralizing
activity against DENV1, 2, 3, and 4. Naïve: plasma samples from naïve donors; DENV: plasma samples
from DENV-immune ZIKV-naïve donors; ZIKV: plasma samples from ZIKV-immune DENV-naïve
donors; DENV/ZIKV: plasma samples from DENV-immune ZIKV-immune donors. Each dot represents
one donor and the bars represent the median value for each group of donors. The p values were
calculated using the nonparametric two-tailed Mann–Whitney test; n.s.: not significant. The dotted line
represents the ELISA cut-off value.
To determine whether these neutralizing antibodies against ZIKV infection could also
cross-neutralize DENV, we evaluated the ability of these antibodies to neutralize the 4 DENV
serotypes. Comparison of the neutralizing activity of samples from DENV-immune ZIKV-naïve
and DENV/ZIKV-immune donors did not reveal any increase in the neutralization titer against the
four DENV serotypes, showing that a subsequent ZIKV infection in DENV-immune donors only
increases the level of ZIKV-neutralizing antibodies without affecting the level of DENV-neutralizing
antibodies (Figure 3C). In addition, no DENV-neutralizing activity was detected in ZIKV donors.
These data confirm previous studies on the induction of ZIKV-specific neutralizing antibodies induced
after ZIKV infection independently of prior DENV immunity [48].
3.5. Decreased Enhancing Potential on ZIKV Infection in DENV/ZIKV-Immune Donors
As DENV infection was previously shown to induce subneutralizing antibodies against DENV1-4
and ZIKV, which could mediate enhancement of DENV and ZIKV infection [17,18,20,21,49,50], we
measured the ADE activity of plasma samples from DENV-immune ZIKV-naïve donors, ZIKV-immune
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DENV-naïve donors, and DENV/ZIKV-immune donors on ZIKV infection and DENV1-4 infection
in vitro. Comparison of the peak enhancement titer between these different samples showed that
plasma samples from DENV-immune ZIKV-naïve (group A) donors have an enhancing potential on
ZIKV infection, whereas plasma samples from ZIKV-immune DENV-naïve (group B) donors do not
have this ADE activity (Figure 4A).
Figure 4. Analysis of Antibody-Dependent Enhancement (ADE) activity of plasma samples on ZIKV
and DENV4 infection. (A) Detection of ADE activity on ZIKV infection from plasma samples of
DENV-immune ZIKV-naïve (higher-left panel), ZIKV-immune DENV-naïve (higher-right panel),
and DENV/ZIKV-immune (lower-left panel) donors. Comparison of the peak enhancement titer
of antibodies from DENV-immune ZIKV-naïve and DENV/ZIKV-immune donors (lower-right panel).
Each dot represents one donor; (B) detection of ADE activity on DENV4 infection from plasma samples
of DENV-immune ZIKV-naïve (higher-left panel), ZIKV-immune DENV-naïve (higher-right panel),
and DENV/ZIKV-immune (lower-left panel) donors. Infectivity curves for each donor are shown.
The p values were calculated using the nonparametric two-tailed Mann–Whitney test. The dotted line
represents the ELISA cut-off value.
More strikingly, a significant decrease in the ADE activity for ZIKV infection was observed in
DENV/ZIKV-immune samples, in comparison with DENV-immune ZIKV-naïve samples (Figure 4A).
These results clearly show that the ADE activity against ZIKV infection, induced after a DENV infection,
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decreases after a subsequent infection with ZIKV. Interestingly, this decrease in the ADE activity was
also observed, albeit to a lesser extent, against DENV4 infection, but not against DENV1, 2, and 3
(Figure 4B). These results highlight the ability of a subsequent ZIKV infection to reduce the enhancing
activity against a DENV4 strain in vitro but not against the other DENV serotypes. Analyses of the
ADE activity using a higher number of DENV-immune ZIKV-naïve and DENV/ZIKV-immune donors
should confirm these results. Interestingly, one out of nine samples from ZIKV-immune DENV-naïve
donors revealed a clear ADE activity on DENV4 infection but not on DENV1-3 infection (Figure 4B).
These results show that ZIKV infection in DENV-naïve donors can induce antibodies with enhancing
activity against DENV4 in some donors, thus confirming previous reports showing the ability of
ZIKV-induced antibodies to enhance DENV infection in vitro [18]. They also show that the ADE
activity against DENV4 is reduced following sequential DENV and ZIKV infection.
3.6. High Titer of Neutralizing Antibodies with Low Enhancing Activity are Associated with Strong
T-Cell Responses
Considering that DENV/ZIKV-immune donors have a higher titer of neutralizing antibodies
against ZIKV in comparison with ZIKV-immune DENV-naïve donors, we wondered whether a
significant correlation could be established between the level of neutralizing antibodies and the
strength of the T-cell response. Although no significant correlation could be drawn between these two
different parameters of the immune response, the analysis of T- and B-cell responses in individual
donors revealed a higher number of DENV/ZIKV-immune donors having both a high neutralizing
antibody response (and low ADE activity) and a strong cross-reactive T-cell response against ZIKV
than ZIKV-immune DENV-naïve donors (Figure 5).
Figure 5. Specificity and cross-reactivity of antibody and T-cell responses from donors with
DENV and/or ZIKV infection. (A) Heat map of the neutralizing activity of plasma samples
from DENV-immune ZIKV-naïve, ZIKV-immune DENV-naïve, and DEN/ZIKV-immune donors
on DENV1-4 and ZIKV infection. (B) Heat map of the ADE activity of plasma samples from
DENV-immune ZIKV-naïve, ZIKV-immune DENV-naïve, and DENV/ZIKV-immune donors on
DENV1-4 and ZIKV infection; (C) Heat map of the mean T-cell response against peptides from the
whole ZIKV proteome (TOTAL) or the immunodominant proteins of PBMCs from ZIKV-immune
DENV-naïve and DENV/ZIKV-immune donors; each column represents one donor.
For instance, six out of eight DENV/ZIKV-immune donors with a Neut50 value higher than 1500
revealed a moderate/low ADE activity (peak titer ≥ 450) on ZIKV infection and a moderate/high
T-cell response (mean SFC/106 PBMC ≥ 100) against E, NS1, NS3, or NS5 (donors 16, 20, 28, 55, 63,
and 66). On the contrary, donors with a moderate/low neutralizing activity against ZIKV (donors
33, 56, and 69, Neut50 ≤ 1500) revealed a moderate/high ZIKV ADE activity (peak titer ≤ 450) and
variable T-cell responses against E, NS1, NS3, or NS5 proteins (Figure 5). Conversely, only one out
of nine ZIKV-immune DENV-naïve donors revealed high neutralizing activity against ZIKV, with
moderate and low T-cell activity against NS3 and NS5, and against E and NS1, respectively. With the
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exception of one donor (donor 21) showing high T-cell activity against NS3 and a moderate/low level
of neutralizing antibodies, all the other ZIKV-immune DENV-naïve donors exhibited low T-cell activity
and a moderate/low level of neutralizing antibodies. These results suggest that cross-reactive T cells,
which are induced after a sequential DENV and ZIKV infection, and exhibit strong functional activity
against specific ZIKV epitopes, could play a role in the induction of antibodies with high neutralizing
potential against ZIKV.
4. Discussion
In this study, using PBMCs from ZIKV-infected human blood donors, we have identified
numerous T-cell epitopes specific to ZIKV or shared between DENV and ZIKV. While the
DENV-specific T-cell responses are predominantly directed against NS3, NS4B, and NS5, the response
against ZIKV mainly targets epitopes in the NS1, NS3, and NS5 proteins. The stronger and broader
IFN-γ response against peptides from the NS5 protein observed in donors previously infected with
DENV led us to postulate that this region contains more peptides recognized by cross-reactive T cells,
whereas the NS1 protein is preferentially targeted by ZIKV-specific T cells, which is consistent with
the higher percentage of identity observed between ZIKV and DENV sequences in the NS5 protein,
in comparison with the NS1 protein.
Among the epitopes activating cross-reactive T cells, several peptides in the NS5 protein matched
the T-cell epitopes recently identified from ZIKV-positive donors, such as the NS52983–06, NS53483–56,
and NS54614–75 peptides recognized by CD8 and CD4 T cells, in the context of HLA-B*35:01 and
HLA-DRB1*07:01, respectively [22]. For several epitopes, the 15-mer or 9-mer peptides matched
epitopes recently identified in transgenic mice expressing human HLA molecules, or in humans
exposed to ZIKV, thus confirming the class I allele restriction for these peptides. This is the case for
15-mer peptide VARVSPFGGLKRLPA inducing a response in a donor expressing the HLA-B*07:02
allele, which contains the C253–5 peptide SPFGGLKRLPA shown to elicit a significant response in
HLA-B*07:02 transgenic mice infected with ZIKV [23]. The same correlations have been established
with NS3 (FPDSNSPIM), NS4B (RGSYLAGASLIYTVT), and NS5 (NQMSALEFYSY) peptides that
induced a strong response in human donors expressing the HLA-B*07:02 and HLA-A*01:01 alleles,
respectively (Table S1), and in transgenic mice expressing these alleles [23]. In other cases, the epitopes
identified in HLA-B*07:02 and HLA-A*01:01 transgenic mice were also identified in responding donors
that nevertheless do not express these alleles, such as the NS32192–33 peptide (Table 2), and the NS1193–3
or the NS5132–7 peptides (Table 3 and Table S1), which elicit a response in donors that express neither
of the two alleles, HLA-B*07:02 or HLA-A*01:01. For these donors, one possibility could be that the
epitope identified in transgenic mice has a higher affinity for a human HLA allele different from the
allele expressed by the transgenic mice, or that the 15-mer peptide contains another epitope that binds
to a different allele. Binding studies with 9-mer epitopes and HLA class I stabilization assays using
TAP-deficient cells should discriminate between these possibilities.
We also reported the identification of several peptides that share common sequences with DENV
and are preferentially targeted by cross-reactive T cells, after DENV and ZIKV infection. Among these
peptides, the NS52933–07 and NS52973–11 peptides contain the amino acid sequence HPYRTWAYH that
shares seven amino acids with an epitope identified in DENV1-positive or in DENV-positive and
ZIKV-positive donors [22,46]. Similarly, the NS53253–39 peptide contains the amino acid sequence
KPWDVVTGV, which is 67% identical to the epitope KPWDVIPMV identified in individuals infected
with DENV1 [46]. Finally, the strongest T-cell responses in DENV/ZIKV-immune donors were
observed with the NS54814–95 peptide or the NS53453–59 and the NS54654–79 peptides (Table 3), which
contain 9-mer epitopes identified previously in DENV-infected individuals [44] or, more recently,
in ZIKV-positive donors, respectively [22]. Altogether, these data reveal the activation of DENV/ZIKV
cross-reactive T cells that dominate the response following sequential DENV and ZIKV infection.
Notably, although these cross-reactive peptides exhibit a high degree of sequence identity with DENV
and can stimulate a T-cell response after DENV infection, they do not induce a response after primary
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infection with ZIKV, suggesting that they are immunodominant in the context of DENV but not in
the context of ZIKV infection. This result is expected, as the immunodominance of an epitope or its
relative abundance depends on the other epitopes expressed by the protein. This is also in agreement
with previous observations showing that epitope production correlates with cleavability of flanking
residues expressed in the protein sequence [51].
Importantly, for these cross-reactive epitopes, the absence of a T-cell response in ZIKV-infected
donors is not simply due to the absence of the presenting HLA allele in this population, as most of the
alleles expressed in responding DENV/ZIKV-immune donors were also expressed in ZIKV-immune
DENV-naïve donors (Table S1). This is what we observed for the NS5132–7, NS52933–07, NS53453–59,
and NS55465–60 epitopes, predicted to be strong binders to the HLA-B*35:01 and HLA-B*40:02 alleles,
respectively, that were frequently expressed by our ZIKV-immune DENV-naïve donors (Table S1).
Altogether, these results show that, in the case of initial ZIKV infection, there is a preferential
recognition of ZIKV-specific epitopes, whereas there is a more frequent and stronger T-cell response
against cross-reactive epitopes after sequential heterologous DENV/ZIKV infection. Interestingly, the
strong T-cell response observed in DENV/ZIKV-immune donors against these NS5 epitopes relies
primarily on donors that express the HLA-B*3501 allele, an allele associated with high-magnitude
responses against DENV, and a stronger protection against DENV infection and disease [25]. As all
blood samples were obtained from donors with asymptomatic ZIKV infection history, we cannot relate
the strength of the ZIKV-specific T-cell response obtained in HLA-B*35:01 donors to the protection
against the disease. Further studies with more subjects with a higher susceptibility to disease following
primary ZIKV infection are required to determine whether, as for DENV, there is an HLA-linked
protective role for T cells in ZIKV infection. Likewise, it would also be important to compare disease
severity in donors having experienced a previous DENV infection or not, to determine whether
cross-reactive T cells induced after DENV infection could mediate a better protection against ZIKV
infection and disease, as recently suggested in mice [23,31]. As both CD4+ and CD8+ T cells were
shown to contribute to protection against DENV infection, a comprehensive analysis of MHC class
II-restricted response is needed to determine the role of CD4 in ZIKV infection and disease protection.
Finally, further phenotypic analyses of ZIKV-specific T cells in asymptomatic or symptomatic donors
will help in defining correlates of protection in natural immunity and vaccination against ZIKV
infection and disease. It will be particularly important to determine whether, as for DENV-specific T
cells, strong responses against ZIKV-specific peptides are more frequent for specific HLA alleles and
are associated with multifunctionality [25].
From the same individuals, we have also shown that, while a primary DENV infection induces
cross-reactive antibodies with enhancing activity against the heterologous DENV serotypes and
against ZIKV, a primary ZIKV infection in naïve donors mainly elicits ZIKV-specific antibodies
with no enhancing activity against DENV. These results do not coincide with the enhancing activity
described in the plasma of one donor infected with ZIKV only [52]. Apart from the fact that the
ADE activity detected in vitro could result from the presence of cross-reactive antibodies induced not
exclusively after DENV or ZIKV infection, this discrepancy could be due to the too-low number of
ZIKV-immune DENV-naïve donors with low neutralizing-antibody titers (three donors with Neut50
values < 300). Alternatively, as the ADE activity in one donor was revealed from day 48 post-onset of
symptoms [52], and since all donors from our cohort were asymptomatic, it is possible that the samples
from ZIKV-immune donors were collected at an early time after infection, prior to the appearance of
enhancing activity against ZIKV infection. In agreement with previous studies, we have also observed
a higher level of cross-reactive antibodies between DENV and ZIKV in donors who have been recently
infected with DENV [17,48,53], as in the case of donors 55, 63, and 66 from group C donors, donors 26
and 53 from group D donors, and donors 20 and 69 from group E donors (Figure 5). Our study also
clearly reveals a significant increase in the titer of neutralizing antibodies against ZIKV infection in
ZIKV-immune donors with previous or current DENV infection (donors from groups C, D, and E),
in comparison with ZIKV-immune DENV-naïve donors (Figure 3B). However, while the increased
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titer of neutralizing antibodies between donors from B and C is still significant, we did not observe
any significant difference in the titer of ZIKV-neutralizing antibodies between donors from groups B
(with sequential DENV and ZIKV infections) and D (DENV-immune with acute ZIKV infection), or
from groups B and E (acute DENV and ZIKV infections). A higher number of donors from groups D
and E should allow us to determine whether there is also an increase in the level of ZIKV-neutralizing
antibodies in donors with acute DENV and/or ZIKV infection. Strikingly, while ZIKV infection
in DENV-immune donors was shown to increase the level of neutralizing antibodies against ZIKV,
in comparison with DENV-naïve donors, it decreases the enhancing activity of antibodies against
ZIKV, in comparison with donors infected only with DENV. These results are consistent with the
inverse correlation observed between the level of neutralizing antibodies and enhancing activity in
DENV-immune donors [54,55]. Interestingly, while ZIKV infection in DENV-immune donors does
not modulate the enhancing potential of antibodies against DENV1-3 infection, it decreases the ADE
activity against DENV4 infection in vitro, a result that could be explained by the higher amino acid
sequence identity in the E protein between ZIKV and DENV4, in comparison with DENV1-3 [56].
Taken together, these results strongly support the activation and clonal expansion of memory
B cells induced after sequential DENV and ZIKV infection, as shown recently in DENV1-infected
individuals [57,58]. These data also show that, while a sequential DENV and ZIKV infection results
in increased neutralization potential and decreased enhancing activity against ZIKV, it does not
affect the level of neutralizing or enhancing antibodies against DENV, suggesting that ZIKV infection
in DENV-immune individuals should not have a significant impact on dengue disease following
subsequent DENV infection. However, as a small fraction of individuals infected with ZIKV were
only shown to express antibodies with enhancing activity against DENV4, it will be important in the
future to analyze in these individuals the impact of ZIKV infection on the outcome of dengue disease
following DENV4 infection. In this sense, it is also worth mentioning that the modulation of ADE
activity measured in vitro does not necessarily reflect the in vivo situation, given in particular the
conflicting results on the impact of pre-existing immunity to DENV on ZIKV pathogenesis [21,59,60].
Finally, in light of the stronger T-cell response and the higher titer in neutralizing antibodies against
ZIKV observed in individuals sequentially infected with DENV and ZIKV, it would be important to
determine whether antigen-specific T follicular-helper (Tfh) cells could be detected in these individuals,
which could account for the activation of memory B cells, as shown recently in PBMC of DENV-infected
patients [61]. In this sense, our study provides a framework for detailed analyses of cell populations
potentially linked to the activation of memory B cells with high neutralization potential against DENV
and ZIKV.
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